Aurobindo Pharma board approves share buyback plan worth Rs 750 cr

The drug firm said July 30 has been fixed as the record date for the Rs 750-crore share buyback scheme through the tender offer route

Aurobindo Pharma, Aurobindo Pharma logo
At the end of June 30, the company promoters owned 51.8 per cent stake, while foreign institutional investors (FIIs) and mutual funds owned 16.73 per cent and 19.17 per cent respectively | Photo: Company website
Press Trust of India New Delhi
1 min read Last Updated : Jul 18 2024 | 10:56 PM IST

Aurobindo Pharma on Thursday said its board has approved a share buyback plan of up to Rs 750 crore.

The company's board has approved the buyback of up to 51,36,986 shares representing up to 0.88 per cent of the total paid-up equity share capital, Aurobindo Pharma said in a regulatory filing.

The company will buy the shares at Rs 1,460 apiece for an aggregate amount of up to Rs 750 crore, it added.

The drug firm said July 30 has been fixed as the record date for the Rs 750-crore share buyback scheme through the tender offer route.

At the end of June 30, the company promoters owned 51.8 per cent stake, while foreign institutional investors (FIIs) and mutual funds owned 16.73 per cent and 19.17 per cent respectively.

Shares of Aurobindo Pharma were trading 2.83 per cent down at Rs 1,332.90 apiece on the BSE.


*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :Aurobindo Pharmapharmaceutical firmsPharma sector

First Published: Jul 18 2024 | 3:39 PM IST

Next Story